We recognize and have recognized for some time that Alzheimer’s disease is a public health crisis,” said Meggie Gaskins.

Biogen Inc (BIIB) reports a 6% revenue increase driven by new product launches, despite facing competitive pressures in its MS franchise.

Donanemab, the newly FDA-approved Alzheimer’s drug, offers monthly infusion treatment that slows early cognitive decline by ...

At this time, I'd like to welcome everyone to the Biogen first quarter 2025 earnings call and business update. (Operator Instructions). Today's conference is being recorded. Thank you. I would now ...

It gets the green light there almost a year after Eisai and Biogen's anti-amyloid rival Leqembi (lecanemab), which was cleared by the NMPA in January. The country is expected to be a major market ...

In 2024, the European Medicines Agency (EMA) approved lecanemab for the treatment of early Alzheimer's disease in patients without contraindications or risk factors for side-effects. This approval ...

MANILA—Malacañang has ordered the dismissal of National Commission of Senior Citizens (NCSC) Commissioner Reymar Mansilungan for serious dishonesty, grave misconduct and conduct prejudicial to the ...

More than 7 million Americans live with Alzheimer’s disease — the highest number ever, according to a new report. Americans want to know if they have the disease and want medication to treat it if ...

The new ApoE4 Alzheimer's Alliance plans to advocate on behalf of patients with this gene variant for more supportive U.S.

Biogen has bought a licence to co-develop and co-market potential Parkinson’s disease drugs with US biotech Denali, in a deal worth more than $2.1 billion. Denali has been working on small ...